Ca(2+)-Currents in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Effects of Two Different Culture Conditions.
Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) provide a unique opportunity to study human heart physiology and pharmacology and repair injured hearts. The suitability of hiPSC-CM critically depends on how closely they share physiological properties of human adult cardiomyocytes (CM). Here we investigated whether a 3D engineered heart tissue (EHT) culture format favors maturation and addressed the L-type Ca(2+)-current (ICa,L) as a readout. The results were compared with hiPSC-CM cultured in conventional monolayer (ML) and to our previous data from human adult atrial and ventricular CM obtained when identical patch-clamp protocols were used. HiPSC-CM were two- to three-fold smaller than adult CM, independently of culture format [capacitance ML 45 ± 1 pF (n = 289), EHT 45 ± 1 pF (n = 460), atrial CM 87 ± 3 pF (n = 196), ventricular CM 126 ± 8 pF (n = 50)]. Only 88% of ML cells showed ICa, but all EHT. Basal ICa density was 10 ± 1 pA/pF (n = 207) for ML and 12 ± 1 pA/pF (n = 361) for EHT and was larger than in adult CM [7 ± 1 pA/pF (p < 0.05, n = 196) for atrial CM and 6 ± 1 pA/pF (p < 0.05, n = 47) for ventricular CM]. However, ML and EHT showed robust T-type Ca(2+)-currents (ICa,T). While (-)-Bay K 8644, that activates ICa,L directly, increased ICa,Lto the same extent in ML and EHT, β1- and β2-adrenoceptor effects were marginal in ML, but of same size as (-)-Bay K 8644 in EHT. The opposite was true for serotonin receptors. Sensitivity to β1 and β2-adrenoceptor stimulation was the same in EHT as in adult CM (-logEC50: 5.9 and 6.1 for norepinephrine (NE) and epinephrine (Epi), respectively), but very low concentrations of Rp-8-Br-cAMPS were sufficient to suppress effects (-logEC50: 5.3 and 5.3 respectively for NE and Epi). Taken together, hiPSC-CM express ICa,L at the same density as human adult CM, but, in contrast, possess robust ICa,T. Increased effects of catecholamines in EHT suggest more efficient maturation.
Department of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-EppendorfHamburg, Germany; Partner Site Hamburg/Kiel/Lübeck, German Centre for Cardiovascular Research (DZHK)Hamburg, Germany.
Ahmet U
AU
Uzun
Department of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-EppendorfHamburg, Germany; Partner Site Hamburg/Kiel/Lübeck, German Centre for Cardiovascular Research (DZHK)Hamburg, Germany.
Ingra
I
Mannhardt
Department of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-EppendorfHamburg, Germany; Partner Site Hamburg/Kiel/Lübeck, German Centre for Cardiovascular Research (DZHK)Hamburg, Germany.
Kaja
K
Breckwoldt
Department of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-EppendorfHamburg, Germany; Partner Site Hamburg/Kiel/Lübeck, German Centre for Cardiovascular Research (DZHK)Hamburg, Germany; Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, University of SzegedSzeged, Hungary.
András
A
Horváth
Partner Site Hamburg/Kiel/Lübeck, German Centre for Cardiovascular Research (DZHK)Hamburg, Germany; Department of General and Interventional Cardiology, University Heart Center HamburgHamburg, Germany.
Silke S
SS
Johannsen
Department of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-EppendorfHamburg, Germany; Partner Site Hamburg/Kiel/Lübeck, German Centre for Cardiovascular Research (DZHK)Hamburg, Germany.
Arne
A
Hansen
Department of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-EppendorfHamburg, Germany; Partner Site Hamburg/Kiel/Lübeck, German Centre for Cardiovascular Research (DZHK)Hamburg, Germany.
Thomas
T
Eschenhagen
Department of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-EppendorfHamburg, Germany; Partner Site Hamburg/Kiel/Lübeck, German Centre for Cardiovascular Research (DZHK)Hamburg, Germany.
Torsten
T
Christ
5-hydroxytryptamine; L-type Ca2+-channel; T-type Ca2+-channel; human induced pluripotent stem cell-derived cardiomyocytes; protein kinase A; β-adrenoceptor
J Mol Cell Cardiol. 2001 Aug;33(8):1515-25
11448139
PLoS One. 2011;6(10 ):e26397
22028871
Naunyn Schmiedebergs Arch Pharmacol. 1992 Nov;346(5):486-9
1470219
Pflugers Arch. 2014 Apr;466(4):791-9
24573175
J Mol Cell Cardiol. 1991 Aug;23(8):929-37
1658345
Cell Stem Cell. 2012 Jan 6;10(1):16-28
22226352
J Physiol. 1974 Oct;242(2):429-51
4376168
J Med Chem. 2012 Jan 26;55(2):697-708
22191557
Channels (Austin). 2011 Nov-Dec;5(6):530-7
21829090
Mol Pharmacol. 1992 Feb;41(2):346-51
1311410
Am J Physiol. 1989 May;256(5 Pt 2):H1505-8
2719143
Assay Drug Dev Technol. 2014 Aug;12(6):352-60
25147907
Front Physiol. 2012 Aug 31;3:346
23015789
PLoS One. 2012;7(9):e45489
23029047
J Mol Cell Cardiol. 2004 Dec;37(6):1147-58
15572045
Pflugers Arch. 2012 Aug;464(2):167-74
22615072
J Biol Chem. 1984 Aug 25;259(16):10020-4
6088478
Pediatr Res. 2001 Nov;50(5):569-74
11641449
Cardiovasc Res. 1999 Oct;44(1):121-31
10615396
J Mol Cell Cardiol. 2006 Oct;41(4):716-23
16889792
Nat Protoc. 2011 May;6(5):689-700
21527925
Channels (Austin). 2011 May-Jun;5(3):251-61
21406960
Circ Res. 2014 Jan 31;114(3):511-23
24481842
Physiol Rev. 2014 Jan;94(1):303-26
24382889
Br J Pharmacol. 1990 Aug;100(4):879-85
2169944
Br J Pharmacol. 2011 Feb;162(4):823-39
20726983
Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):11193-8
25024212
Circ Res. 2000 Mar 31;86(6):628-35
10746997
Receptors Channels. 1995;3(2):71-81
8581402
Am J Physiol Heart Circ Physiol. 2011 Nov;301(5):H2006-17
21890694
J Membr Biol. 1990 Jun;116(1):9-17
2165178
Naunyn Schmiedebergs Arch Pharmacol. 1992 Nov;346(5):482-5
1335123
Methods Mol Biol. 2014;1181:121-9
25070332
J Mol Cell Cardiol. 1994 Oct;26(10):1307-20
7869391
Nature. 1983 Jun 9-15;303(5917):535-7
6190088
PLoS One. 2012;7(7):e41958
22860038
Circulation. 2004 Oct 26;110(17):2651-7
15492323
Circulation. 2013 Sep 10;128(11 Suppl 1):S3-13
24030418
Circulation. 2000 Aug 8;102(6):692-7
10931811
J Mol Cell Cardiol. 1991 Jan;23(1):41-54
1709972
Am J Physiol. 1995 Nov;269(5 Pt 2):H1695-703
7503267
Annu Rev Physiol. 1983;45:341-58
6303205
Am J Physiol. 1997 Jan;272(1 Pt 2):H227-35
9038942
Naunyn Schmiedebergs Arch Pharmacol. 1990 Mar;341(3):232-9
1692975
Biochem Soc Trans. 2010 Aug;38(4):1037-45
20659000
Am J Physiol. 1989 May;256(5 Pt 2):H1478-92
2470265
J Physiol. 1988 Jan;395:233-53
2457676
J Physiol. 1992 Aug;454:657-72
1335509
Am J Physiol. 1991 Aug;261(2 Pt 2):H364-79
1652211
Nat Methods. 2014 Aug;11(8):855-60
24930130
Circ Res. 2002 Sep 20;91(6):517-24
12242270
Naunyn Schmiedebergs Arch Pharmacol. 2004 Dec;370(6):474-83
15599709
Eur Heart J. 1989 Jun;10 Suppl B:29-37
2572419
Nature. 2011 Mar 10;471(7337):230-4
21307850
J Mol Cell Cardiol. 2010 Jan;48(1):65-70
19729018
J Mol Cell Cardiol. 2010 Jan;48(1):161-71
19747484
Proc Natl Acad Sci U S A. 1986 Jul;83(14):5340-4
2425366